Ceryvyn Therapeutics (CYV) Q1 2027 TU earnings summary

Executive summary

• CYV-101 Stage 1 LAM preclinical biology and inhalation work continued; nebulisation feasibility and preliminary animal safety and tolerability studies remain on track.

• Planned clinical development advanced through a Polarian Xe-MRI agreement, Stage 2 CRO selection after quarter-end, patient engagement planning and the inaugural Scientific Advisory Board meeting.

Financial highlights

• Cash and equivalents were AUD $27.463m at 30 September 2026, down from AUD $30.021m at 30 June 2026; operating cash outflow was AUD $2.364m.

• Operating cash outflow increased from AUD $1.1m in the previous quarter; interest income was AUD $0.3m.

• Cash flow included a negative AUD $194k foreign-exchange movement; quarter-end cash comprised AUD $3.915m in bank balances and AUD $23.548m in call deposits.

Outlook and guidance

• Stage 1 preclinical biology and inhalation studies are underway; progression between the three development stages depends on predefined scientific, operational and capital allocation criteria reviewed by the Board.

• The selected Australian-based CRO is expected to support Stage 2 protocol development, ethics submissions, site feasibility, nebulised dosing materials, safety monitoring and data services; scope and budget will be refined as study requirements are confirmed.